Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338183 | 0.93 | NR5A2 (0.43) | MCHR1CYP3A4CYP2C19NR5A2KDM4E | |
| SCHEMBL1339551 | 0.93 | MCHR1 (0.37) | MCHR1CYP3A4CYP2C19OPRM1OPRK1 | |
| SCHEMBL1337038 | 0.88 | MARS1 (0.39) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1339409 | 0.88 | HSD11B1 (0.36) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1336885 | 0.86 | CNR1 (0.37) | CYP3A4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL1336826 | 0.85 | CNR1 (0.35) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1337210 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1338637 | 0.84 | GABRA1 (0.38) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1338200 | 0.83 | GABRA1 (0.36) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL1338169 | 0.83 | GABRA1 (0.37) | KDM4EALDH1A1GAAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1940840-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045758-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | MCHR1 2856/4885CYP3A4 8/4885CYP2C19 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.